Azithromycin Combination Therapy for Malaria
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00299208|
Recruitment Status : Completed
First Posted : March 6, 2006
Last Update Posted : August 27, 2010
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Plasmodium Falciparum Malaria||Drug: Artesunate Drug: Azithromycin Drug: Quinine||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria|
|Actual Primary Completion Date :||July 2005|
|Actual Study Completion Date :||July 2005|
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||20 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Acute symptomatic falciparum malaria infection as determined by malaria smear with a parasite density of 100 to 100,000 asexual parasites/µL with fever, defined as >37.5ºC, during the current illness, or history (within the last 48 hours) of fever.
- Age: 20-65 years old
- Male or female. All females are required to have a negative human chorionic gonadotropic (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years post menopausal) are required to use an acceptable method of contraception, such as implant, injectable, oral contraceptive(s) with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study.
- Written informed consent obtained.
- Willing to stay hospitalized for 28 days for treatment and observations.
- Otherwise healthy outpatients (with no other clinically-significant illnesses as described in Exclusion Criteria, #6).
- Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception (as described in Inclusion Criteria, #3).
- Mixed malaria infection on admission by malaria smear.
- A previous state of intolerance or hypersensitivity to the study drugs quinine, artesunate, or azithromycin or to drugs with similar chemical structures (quinidine, any artemisinin derivative, and macrolides such as erythromycin).
- Malaria drug therapy administered in the past 30 days by history (quinine, chloroquine, mefloquine, artemisinin derivatives, sulfadoxine/pyrimethamine, lumefantrine).
- Previous participation in this trial, or participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study.
- Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e..g. malignancy or conditions that may effect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically).
Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk. Specifically, the following will serve as exclusionary laboratory values:
- Creatinine > 1.4 X ULN (>2.0 mg/dl),
- Glucose < LLN (75 mg/dl),
- AST, ALT > 3x ULN (120 U/L), or
- Prolonged QT wave on baseline electrocardiogram (QT >0.45s)
- Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).
- Signs or symptoms of severe malaria.
- Anyone who received a transfusion of red blood cells within the prior 30 days.
- Unable and/or unlikely to comprehend and/or follow the protocol.
- Self-reported alcohol and/or any other drug abuse.
- Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00299208
|Mahidol University Hospital for Tropical Diseases|
|Bangkok, Thailand, 10270|
|Other Study ID Numbers:||
|First Posted:||March 6, 2006 Key Record Dates|
|Last Update Posted:||August 27, 2010|
|Last Verified:||March 2010|
Vector Borne Diseases
Muscle Relaxants, Central
Physiological Effects of Drugs
Peripheral Nervous System Agents
Sensory System Agents